Trial Profile
A Phase 1 Study of MLN9708 in Japanese Patients with Relapsed and/or Refractory Multiple Myeloma
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Ixazomib (Primary) ; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Takeda
- 13 Feb 2020 Status changed from completed to discontinued.
- 01 Apr 2017 Results published in the International Journal of Hematology
- 07 Jun 2016 New trial record